Combination of fludarabine (FAMP) cyclophosphamide (CTX) and alemtuzumab for patients with relapsed chronic lymphocytic leukemia (CLL).

被引：0
|
作者：
Tedeschi, A
Montillo, M
Miqueleiz, S
Draisci, M
Ricci, F
Scarpati, B
Mura, ME
Crugnola, M
Morra, E
机构：
[1] Univ Parma, Hematol & Transplant Unit, I-43100 Parma, Italy
[2] Osped Niguarda Ca Granda, Dept Pathol, Milan, Italy
[3] Osped Niguarda Ca Granda, Lab Transplant Immunol, Milan, Italy
[4] Osped Niguarda Ca Granda, Dept Hematol, Milan, Italy
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5036
引用
收藏
页码：341B / 341B
页数：1
相关论文
共 50 条
  • [1] Fludarabine (FAMP) and cyclophosphamide (CTX) combination in chronic lymphocytic leukemia (CLL).
    Gonzalez, H
    Cazin, B
    Dighiero, G
    Merle-Béral, H
    Vernant, JP
    Binet, JL
    Maloum, K
    BLOOD, 1998, 92 (10) : 277B - 277B
  • [2] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL)
    OBrien, S
    Kantarjian, H
    Beran, M
    Lerner, S
    Gilbreath, J
    Keating, MJ
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 453 - 453
  • [3] Fludarabine (FAMP) and cyclophosphamide (CTX) therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Freireich, E
    Komblau, S
    Koller, C
    Lerner, S
    Gilbreath, J
    Keating, M
    BLOOD, 1996, 88 (10) : 1910 - 1910
  • [4] EFFICACY OF COMBINATION FLUDARABINE AND ALEMTUZUMAB IN PATIENTS WITH RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
    Zagoskina, T.
    Zotina, E.
    Malykh, O.
    HAEMATOLOGICA, 2012, 97 : 305 - 305
  • [5] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    Elter, T.
    James, R.
    Busch, R.
    Winkler, D.
    Ritgen, M.
    Boettcher, S.
    Kahl, C.
    Gassmann, W.
    Stauch, M.
    Hasan, I.
    Staib, P.
    Fischer, K.
    Fink, A-M
    Bahlo, J.
    Buehler, A.
    Doehner, H.
    Wendtner, C-M
    Stilgenbauer, S.
    Engert, A.
    Hallek, M.
    LEUKEMIA, 2012, 26 (12) : 2549 - 2552
  • [6] Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia
    T Elter
    R James
    R Busch
    D Winkler
    M Ritgen
    S Böttcher
    C Kahl
    W Gassmann
    M Stauch
    I Hasan
    P Staib
    K Fischer
    A-M Fink
    J Bahlo
    A Bühler
    H Döhner
    C-M Wendtner
    S Stilgenbauer
    A Engert
    M Hallek
    Leukemia, 2012, 26 : 2549 - 2552
  • [7] Fludarabine (FAMP) and mitoxantrone therapy in chronic lymphocytic leukemia (CLL).
    OBrien, S
    Kantarjian, H
    Beran, M
    Robertson, IE
    Freireich, E
    Kornblau, S
    Koller, C
    Estey, E
    Lerner, S
    Keating, M
    BLOOD, 1996, 88 (10) : 2341 - 2341
  • [8] Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) for patients with relapsed chronic lymphocytic leukemia (CLL).
    O'Brien, S.
    Byrd, J. C.
    Kipps, T. J.
    Forero-Torres, A.
    Flinn, I. W.
    Wynne, D. I.
    Molina, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 360S - 360S
  • [9] Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL).
    Garcia-Manero, G
    O'Brien, S
    Cortes, J
    Giles, F
    Faderl, S
    Lerner, S
    Albitar, M
    Kantarjian, HM
    Keating, MJ
    BLOOD, 2000, 96 (11) : 757A - 757A
  • [10] Combined fludarabine, cyclophosphamide, and alemtuzumab (FCC), an active regimen for treated patients with chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Ricci, Francesca
    Vismara, Eleonora
    Ciapanna, Denis
    Petrizzi, Valeria Belsito
    Crugnola, Monica
    Spriano, Mauro
    Uziel, Lilj
    De Blasio, Angelo
    Spedini, Pierangelo
    Morra, Enrica
    BLOOD, 2007, 110 (11) : 922A - 922A
12345